胃癌市場：KOL 洞察

本報告調查全球胃癌市場，提供了有關胃癌的市場概況和信息，從Herceptin和trastuzumab生物仿製藥在一線治療中的作用演變，到Enhertu 在二線治療中的廣闊潛力，深入挖掘最新進展。一線的 KOL 對目前的治療方法和新選擇進行了全面分析，強調了主要挑戰和未來機會。

目錄

執行摘要

目前與未來的治療演算法

研究目的

上市治療

• 化療方案、當前治療趨勢、挑戰和未滿足的需求
  • Herceptin (trastuzumab; Roche)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
  • Cyramza (ramucirumab; Lilly)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)

後期管道計劃

• 免疫治療
  • Durvalumab (Imfinzi; AstraZeneca)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Atezolizumab (Tecentriq; Roche)
• 標靶生物治療
  • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
  • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte
  • Bemarituzumab (Five Prime Therapeutics/Amgen)
  • Zanidatamab (ZW25; Zymeworks)
  • Evorpacept (ALX Oncology)
  • Catumaxomab (Removab; LintonPharm)
  • ARX788 (Ambrx/Zhejiang Medicine)
• 標靶口服治療
  • Stivarga (regorafenib; Bayer)
• 下一代治療
  • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

未來治療趨勢

• 細胞療法與胃癌疫苗
  • 胃癌治療中其他有前景的技術

附錄

新聞

From the evolving role of Herceptin and trastuzumab biosimilars in first-line therapy to the promising potential of Enhertu in second-line treatment, this report delves into the latest advancements in gastric cancer therapies. Leading KOLs provide a thorough analysis of current treatments and emerging options, highlighting key challenges and future opportunities. Discover how these insights are set to transform the gastric cancer treatment landscape.

Table of Contents

Executive summary

Current and future treatment algorithm

Research objectives

Marketed treatments

• Chemotherapy regimens, current treatment trends, challenges and unmet needs
  • Herceptin (trastuzumab; Roche)
  • Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
  • Cyramza (ramucirumab; Lilly)
  • Keytruda (pembrolizumab; Merck & Co.)
  • Opdivo (nivolumab; BMS/Ono)

Late-stage pipeline programmes (120)

• Immunotherapies
  • Durvalumab (Imfinzi; AstraZeneca)
  • Avelumab (Bavencio; Merck Group/Pfizer)
  • Atezolizumab (Tecentriq; Roche)
• Targeted biologic therapies
  • Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
  • Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
  • Bemarituzumab (Five Prime Therapeutics/Amgen)
  • Zanidatamab (ZW25; Zymeworks)
  • Evorpacept (ALX Oncology)
  • Catumaxomab (Removab; LintonPharm)
  • ARX788 (Ambrx/Zhejiang Medicine)
• Targeted oral therapies
  • Stivarga (regorafenib; Bayer)
• Next-generation therapies
  • Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)

Future treatment trends

• Cell therapies and gastric cancer vaccines
  • Other promising technologies in the pipeline for gastric cancer

Appendix

• KOL details
  • KOLs from the USA
  • KOLs from Europe

News